The motion picture you are about to witness may startle you. It would not have been possible, otherwise, to sufficiently emphasize the frightful toll of the new drug menace which is destroying the youth of America in alarmingly increasing numbers. Marijuana. it’s that drug - a violent narcotic - an unspeakable scourge - The Real Public Enemy Number One!
The above appeared in the opening of Reefer Madness, a film released in 1936, right before the audience would embark on a tale about a group of teenagers whose rapid downfall is caused by, you guessed it, marijuana. Particularly in the early days of Hollywood, movies served as a powerful and persuasive form of media, so it should come as no surprise that this melodramatic film rooted in American drug politics is now viewed as a campy cult classic. Before being purchased by producer Dwain Esper, who would later re-cut and distribute the film on the exploitation circuit, the film was originally funded by a church group intending to demonstrate to concerned parents the dangers of cannabis. Now viewed from time to time on the midnight screening circuit, the behavior portrayed in the film is more likely to get a laugh than incite fear about falling into a life of“sin, degradation, vice, and insanity,” especially since there are currently 23 states and the District of Columbia with laws that legalize marijuana in some form.
While those who carry a medical cannabis prescription or use recreationally should use responsibly, continued cannabis research has discovered that Marijuana can be a friend, rather than a foe, to the medical industry. Studies have shown that marijuana can bring significant relief to the sick and ailing. One company, InMed Pharmaceuticals Inc. (IN:CNX), a clinical stage biopharmaceutical company, is working to understand the chemistry of marijuana and its potential benefits to the field of medicine.
This Cannabinoid is Not Like The Others
Cannabis consists of over 500 natural compounds, with at least 85 of those compounds being cannabinoids. Cannabinoids are a group of active compounds that are responsible for marijuana’s effects on the body. Simply put, cannabinoids are responsible for that “high” feeling. They also happen to be the reason that medical marijuana has been linked to the relief of symptom-related ailments.
Two of the 85 cannabinoids are the most widely known: tetrahydrocannabinol (THC) and cannabidiol (CBD). Unlike THC, which is a psychoactive cannabinoid, CBD is a non-psychoactive cannabinoid believed to have numerous medicinal benefits, including mood improvement, pain relief, antipsychotic properties, and anti-inflammatory properties.
InMed Pharmaceuticals specializes in the research and development of novel, cannabinoid-based therapies, combined with innovative drug delivery systems, InMed is utilizing its proprietary Intelligent Cannabinoid Drug Design Platform to identify new bioactive compounds within the cannabis plant that interact with certain genes that are responsible for specific diseases.
Currently, two products are in the company’s development pipeline: INM-750, for the treatment of Epidermolysis Bullosa, and INM-085, for the treatment of glaucoma. InMed's development pipeline also includes product candidates for glaucoma, arthritis, and epidermolysis bullosa (EBS), as well as active discovery programs in orofacial pain, ocular allergies, and chronic obstructive pulmonary disease (COPD).
Bringing a Strong Close to 2015
2015 proved to be an exciting year for the Vancouver-based company. InMed’s operational highlights include:
- Forming an exclusive strategic collaboration with the University of Debrecen, Hungary, to develop novel phytocannabinoid-based therapies to treat ocular allergic symptoms.
- Receiving a notice from Health Canada dated March 12, 2015, approving InMed's application for an exemption under Section 56 of the Controlled Drugs and Substances Act.
- Awarding a grant from Mitacs, a leading Canadian non-profit organization that accelerates innovative projects through strategic academic and industry collaboration, to further develop the Company's proprietary nanoparticle-based delivery system for their leading drug candidate CTI-085 for glaucoma.
- Eligibility for book-entry delivery and depository services of The Depository Trust Company (the "DTC") to facilitate electronic settlement of transfers of its common shares in the United States.
- Filing a provisional patent application with the United States Patent and Trademark Office ("USPTO") relating to the treatment of eye diseases.
- Filing a provisional patent application with the United States Patent and Trademark Office ("USPTO") relating to the treatment of Epidermolysis Bullosa Simplex (EBS) using novel formulations of natural cannabinoid compounds developed by InMed.
- Initiating a program to identify and evaluate cannabinoid compounds for the treatment of chronic obstructive pulmonary disease (COPD).
Furthermore, In August, the company announced the successful completion and validation of a preclinical pain model using nerve growth factor (NGF) induced pain in rats. Preliminary data indicates that primary afferent neurons innervating the masseter muscles of female rats expressed CB1 and CB2 and these expressions were found in satellite glial cells in the trigeminal ganglion.
"These results suggest that in pain conditions where the level of NGF is elevated, pain is mediated, in part, by the reduction of the inhibitory input by the endo-cannabinoid system in the periphery,” said Dr. Sazzad Hossain, Chief Scientific Officer of Inmed Pharmaceuticals. “Peripheral application of cannabinoids may counter this effect and provide analgesic relief.”
So Long to Reefer Madness
Thanks to science and innovative companies like InMed, cannabis is no longer considered, by most, as The Real Public Enemy Number One. InMed's proprietary Intelligent Cannabinoid Drug Design Platform (IDP), therapeutic product pipeline, and accelerated developments position the company to be at the forefront of a fascinating and booming industry.
For more information about InMed Pharmaceuticals, visit www.inmedpharma.com.
Disclosure: In the purview of Section
17(B) of the Securities Act of 1933 and in the interest of full
disclosure, we call the reader's attention the fact that
Equities.com, Inc. may be compensated by the companies profiled in
the Spotlight Companies section. The purpose of these profiles is to
provide awareness of these companies to investors in the micro,
small-cap and growth equity community and should not in any way come
across as a recommendation to buy, sell or hold these securities.
Equities.com is not a registered broker, broker dealer, investment
advisor, analyst, investment banker or underwriter. All profiles are
based on information that is available to the public. The information
contained herein should not be considered to be all-inclusive and is
not guaranteed by Equities.com to be free from misstatement or
errors. Readers are reminded to do their own due diligence when
researching any companies mentioned on this website.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer